Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Curcumin  COVID-19 treatment studies for Curcumin  C19 studies: Curcumin  Curcumin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 82% Improvement Relative Risk Mortality (b) 60% Mortality (c) 91% Mortality (d) 67% Pawar et al. Curcumin for COVID-19 RCT EARLY TREATMENT Is early treatment with curcumin beneficial for COVID-19? Double-blind RCT 140 patients in India Lower mortality with curcumin (p=0.017) Pawar et al., Frontiers in Pharmacology, doi:10.3389/fphar.2021.669362 Favors curcumin Favors control
Oral Curcumin With Piperine as Adjuvant Therapy for the Treatment of COVID-19: A Randomized Clinical Trial
Pawar et al., Frontiers in Pharmacology, doi:10.3389/fphar.2021.669362, CTRI/2020/05/025482
Pawar et al., Oral Curcumin With Piperine as Adjuvant Therapy for the Treatment of COVID-19: A Randomized Clinical Trial, Frontiers in Pharmacology, doi:10.3389/fphar.2021.669362, CTRI/2020/05/025482
May 2021   Source   PDF  
  All Studies   Meta
RCT 140 patients, 70 treated with curcumin and piperine (for absorption), and 70 treated with probiotics, showing faster recovery, lower progression, and lower mortality with curcumin.
risk of death, 81.8% lower, RR 0.18, p = 0.02, treatment 2 of 70 (2.9%), control 11 of 70 (15.7%), NNT 7.8.
risk of death, 60.0% lower, RR 0.40, p = 0.39, treatment 2 of 15 (13.3%), control 5 of 15 (33.3%), NNT 5.0, severe group.
risk of death, 90.9% lower, RR 0.09, p = 0.05, treatment 0 of 25 (0.0%), control 5 of 25 (20.0%), NNT 5.0, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), moderate group.
risk of death, 66.7% lower, RR 0.33, p = 1.00, treatment 0 of 30 (0.0%), control 1 of 30 (3.3%), NNT 30, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), mild group.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Pawar et al., 28 May 2021, Double Blind Randomized Controlled Trial, India, peer-reviewed, 8 authors, this trial compares with another treatment - results may be better when compared to placebo, trial CTRI/2020/05/025482.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperCurcuminAll
Abstract: CLINICAL TRIAL published: 28 May 2021 doi: 10.3389/fphar.2021.669362 Oral Curcumin With Piperine as Adjuvant Therapy for the Treatment of COVID-19: A Randomized Clinical Trial Kirti S Pawar 1*, Rahul N Mastud 1, Satheesh K Pawar 2, Samragni S Pawar 3, Rahul R Bhoite 4, Ramesh R Bhoite 1, Meenal V Kulkarni 5 and Aditi R Deshpande 6 1 Giriraj Hospital and Intensive Care unit, Baramati, India, 2Siddhivinayak Ultrasound Research Center, Baramati, India, 3HBT Medical College and Dr R N Cooper Municipal General Hospital, Mumbai, India, 4Medstar Good Samaritan Hospital, Baltimore, MD, United States, 5Department of Preventive and Social Medicine, N K P Salve Medical College Nagpur, Nagpur, India, 6 Freelance Statistician, Nagpur, India Edited by: Dâmaris Silveira, University of Brasilia, Brazil Reviewed by: Omar Estrada, Instituto Venezolano de Investigaciones Científicas (IVIC), Venezuela Bharat B Aggarwal, University of Texas MD Anderson Cancer Center, United States *Correspondence: Kirti S. Pawar Specialty section: This article was submitted to Ethnopharmacology, a section of the journal Frontiers in Pharmacology Received: 18 February 2021 Accepted: 20 April 2021 Published: 28 May 2021 Citation: Pawar KS, Mastud RN, Pawar SK, Pawar SS, Bhoite RR, Bhoite RR, Kulkarni MV and Deshpande AR (2021) Oral Curcumin With Piperine as Adjuvant Therapy for the Treatment of COVID-19: A Randomized Clinical Trial. Front. Pharmacol. 12:669362. doi: 10.3389/fphar.2021.669362 Background: Coronavirus disease-2019 (COVID-19) has a wide range of pathophysiological effects. Curcumin, an active constituent of Curcuma longa (turmeric), has several properties, including anti-inflammatory, antioxidant, antiviral, antithrombotic, and anti-proliferative effects, which make it a promising candidate for the symptomatic treatment of COVID-19. Objective: We aimed to determine the effects of curcumin administered with piperine (to optimize absorption) on symptoms in patients with COVID-19 in a double-blind, randomized, controlled trial at a 30-bed dedicated COVID Health Center (DCHC) in Maharashtra, India. Methods: In addition to conventional COVID-19 treatment, patients in the control group received a dose of probiotics twice a day, and patients in the study group received curcumin (525 mg) with piperine (2.5 mg) in tablet form twice a day. The effects of curcumin/piperine treatment on primary and secondary outcomes were assessed for the duration of hospitalization. Results: Patients with mild, moderate, and severe symptoms who received curcumin/ piperine treatment showed early symptomatic recovery (fever, cough, sore throat, and breathlessness), less deterioration, fewer red flag signs, better ability to maintain oxygen saturation above 94% on room air, and better clinical outcomes compared to patients of the control group. Furthermore, curcumin/piperine treatment appeared to reduce the duration of hospitalization in patients with moderate to severe symptoms, and fewer deaths were observed in the curcumin/piperine treatment group. Conclusions: Administration of oral curcumin with piperine as an adjuvant symptomatic therapy in COVID-19 treatment could substantially reduce morbidity and mortality, and ease the logistical and supply-related burdens on the healthcare system. Curcumin could be a safe and natural therapeutic option to prevent Post-Covid thromboembolic events. identifier: CTRI/2020/05/025482 Keywords: curcumin,..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop